Search
×
FR

Placeholder headline

This is just a placeholder headline

API STD 521: Guide for Pressure-relieving and Depressuring Systems – Edition 6

$

682

BUY NOW

Placeholder headline

This is just a placeholder headline

API STD 653: Tank Inspection, Repair, Alteration, and Reconstruction – Edition 4

$

507

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA Z662:19 – Oil and gas pipeline systems

$

1197

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA Z341 Series-18: Storage of hydrocarbons in underground formations

$

878

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA Z246.2-14 – Emergency preparedness and response for petroleum and natural gas industry systems

$

596

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA Z341 Series:22 – Storage of hydrocarbons in underground formations

$

878

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA Z731-09 (R2014) – Emergency Preparedness and Response

$

177

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA Z662:23 – Oil and gas pipeline systems

$

1197

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA Z341 Series:26 – Storage of Hydrocarbons in underground formations

$

878

BUY NOW

Placeholder headline

This is just a placeholder headline

CSA B51:24 Boiler, Pressure Vessel, and Pressure Piping Code

$

389

BUY NOW

ISO 17593:2022

ISO 17593:2022 Clinical laboratory testing and in vitro medical devices – Requirements for in vitro monitoring systems for self-testing of oral anticoagulant therapy

CDN $379.00

SKU: 84af812bb951 Category:

Description

This document specifies requirements for in vitro measuring systems for self-monitoring of vitamin-K antagonist oral anticoagulation therapy, including performance, quality assurance and user training and procedures for the validation of performance by the intended users under actual and simulated conditions of use.

This document applies solely to prothrombin time measuring systems used by lay persons for monitoring their own vitamin-K antagonist oral anticoagulation therapy, and which report results as international normalized ratios (INR).

This document is applicable to manufacturers of such systems and those other organizations (e.g. regulatory authorities and conformity assessment bodies) having the responsibility for assessing the performance of these systems.

This document is not applicable to:

-    in vitro measuring systems for coagulation quantities assessing vitamin-K antagonist oral anticoagulation therapy used by physicians or healthcare providers;

-    non-vitamin-K antagonist oral anticoagulation therapy (e.g. dabigatran);

-    a comprehensive evaluation of all possible factors that can affect the performance of these systems;

-    the medical aspects of oral-anticoagulation therapy.

Edition

2

Published Date

2022-03-11

Status

PUBLISHED

Pages

53

Language Detail Icon

English

Format Secure Icon

Secure PDF

Abstract

This document specifies requirements for in vitro measuring systems for self-monitoring of vitamin-K antagonist oral anticoagulation therapy, including performance, quality assurance and user training and procedures for the validation of performance by the intended users under actual and simulated conditions of use.

This document applies solely to prothrombin time measuring systems used by lay persons for monitoring their own vitamin-K antagonist oral anticoagulation therapy, and which report results as international normalized ratios (INR).

This document is applicable to manufacturers of such systems and those other organizations (e.g. regulatory authorities and conformity assessment bodies) having the responsibility for assessing the performance of these systems.

This document is not applicable to:

-    in vitro measuring systems for coagulation quantities assessing vitamin-K antagonist oral anticoagulation therapy used by physicians or healthcare providers;

-    non-vitamin-K antagonist oral anticoagulation therapy (e.g. dabigatran);

-    a comprehensive evaluation of all possible factors that can affect the performance of these systems;

-    the medical aspects of oral-anticoagulation therapy.

Previous Editions

Can’t find what you are looking for?

Please contact us at: